ArticleVaccines2026

Generating Patient-Specific Anti-Tumor Responses with Non-Genetically Altered 'Off-the-Shelf' Allogeneic Cell Therapy: Leveraging Allo-Incompatibility for In Situ Vaccination.

Michael Har-NoyPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.